Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Comparative Effectiveness of Chatgpt 4.0 and Gemini Advanced in Diagnosing Challenging Hematologic Cases

Ibrahim Khamees, Xiangni Wu, Hana Qasim, Anas Al-sadi, Ma'in Abumuhfouz, Abdulraheem Yacoub, Haoran Li

Blood (2024) 144 (Supplement 1): 7501.

https://doi.org/10.1182/blood-2024-198703

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Moazzam Shahzad, Sohaib Irfan, Muhammad Kashif Amin, Muhammad Jawad Javed, Matthew McGuirk, Sibgha Gull Chaudhary, Iqra Anwar, Zobia Farooq, Abdulraheem Yacoub, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2024-193477

Published: 2024

Journal Articles

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, Praneeth Baratam, Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, Ben K. Tomlinson, Jay Yang, Pankit Vachhani, Joseph G Jurcic, Caspian H. Oliai, Jessica Liegel, Edward Pearson, Anna Van Rhenen, Marcello Rotta, Kapil Rathi, Juan Pinelli, Tara Chen, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2024-199634

Published: 2024

Journal Articles

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Daniel Winokur, Brian Mulherin, Abdulraheem Yacoub, Soyon Lee, Ver Bilano, Glorian Yen, Anumaxine Geevarghese, Jincy Paulose, Annie Guerin, Dominick Latremouille-Viau, Rebecca Bungay, Gayatri Marathe, Anem Waheed

Blood (2024) 144 (Supplement 1): 7553.

https://doi.org/10.1182/blood-2024-199147

Published: 2024

Journal Articles

Systematic Approach to Treatment De-Escalation While Maintaining Remission in CML, a Risk Mitigation and Cost Reduction Study

Nicole Twardowski, Razan Mansour, Jianzheng Wu, Dinesh Pal Mudaranthakam, Leah Diebolt, Abdulraheem Yacoub

Blood (2024) 144 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2024-198636

Published: 2024

Journal Articles

Pilot Phase II Trial of the Combination of Tagraxofusp with Pacritinib in Patients with Myelofibrosis, Tagpac Study

Abdulraheem Yacoub, Tara L. Lin, Heather J Male, Kenneth P Byrd, Haitham Abdelhakim, Lisa Stewart, Maddie Jensen, Jesus D Gonzalez Lugo

Blood (2024) 144 (Supplement 1): 6641.

https://doi.org/10.1182/blood-2024-194439

Published: 2024

Journal Articles

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Abdulraheem Yacoub, Ghaith Abu-Zeinah, Albert Qin, Weichung Joe Shih, Waleed Da'na, Tsewang Tashi, Oleh Zagrijtschuk, Robert Geller, Harinder Gill

Blood (2024) 144 (Supplement 1): 6626.

https://doi.org/10.1182/blood-2024-199337

Published: 2024

Journal Articles

Long Term Clinical and Molecular Responses in Patients with Polycythemia Vera and Essential Thrombocytosis Receiving Pegylated Interferon-Alpha Therapy

Leah Diebolt, Nicole Twardowski, Jayda Esplund, Jianzheng Wu, Dinesh Pal Mudaranthakam, Abdulraheem Yacoub

Blood (2024) 144 (Supplement 1): 6682.

https://doi.org/10.1182/blood-2024-201840

Published: 2024

Journal Articles

Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study

Abdulraheem Yacoub, Ellen K. Ritchie, Naveen Pemmaraju, Richard Zuniga, Erin L. Crowgey, Cynthia Timmers, Patricia Feldman, J.E. Hamer-Maansson, Tricia Kalafut, Evan M. Braunstein, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2024-199810

Published: 2024

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis

Moazzam Shahzad, Muhammad Kashif Amin, Ben Ponvilawan, Hana Qasim, Matthew McGuirk, Sibgha Gull Chaudhary, Iqra Anwar, Abat Khan, Abdulraheem Yacoub, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2024-193357

Published: 2024

Journal Articles

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Aaron T. Gerds, Andrew T. Kuykendall, Marina Kremyanskaya, Ellen K. Ritchie, Jason Gotlib, Jeanne Palmer, Kristen M. Pettit, Victor Priego, Uttam Kumar Nath, Abdulraheem Yacoub, Arkapal Bandyopadhyay, Suneel Gupta, Sarita Khanna, Arturo Molina, Naveen Pemmaraju

Blood (2024) 144 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2024-197985

Published: 2024

Journal Articles

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

Julian Waksal, Ronald Hoffman, Abdulraheem Yacoub, Francesco Passamonti, Aaron T. Gerds, Vikas Gupta, Grace Van Hyfte, Jayanshu Jain, Margherita Maffioli, Natalia Rosas, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2023-182116

Published: 2023

Journal Articles

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

Andrew T. Kuykendall, Abdulraheem Yacoub, Nancy Reaven, Susan Funk, Pedro Oyuela, Frank Valone, Phil Dinh, Lucy Bellamy, Nikita Modi, Arturo Molina, Suneel Gupta

Blood (2023) 142 (Supplement 1): 137.

https://doi.org/10.1182/blood-2023-180309

Published: 2023

Journal Articles

The Diagnostic Value of Circulating Blasts in Patients with Myeloproliferative Neoplasms in Accelerated or Blast Phase

Abdulraheem Yacoub, Shirene Philipose

Blood (2023) 142 (Supplement 1): 6422.

https://doi.org/10.1182/blood-2023-184761

Published: 2023

Journal Articles

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Claire N Harrison, Alessandro Maria Vannucchi, Christian Recher, Francesco Passamonti, Aaron T. Gerds, Juan Carlos Hernandez Boluda, Abdulraheem Yacoub, Shireen Sirhan, Jun Kawashima, Bharat Patel, Bryan Strouse, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2023-178816

Published: 2023

Journal Articles

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Pankit Vachhani, Abdulraheem Yacoub, Elie Traer, Lina Benajiba, Francesco Passamonti, Ashwin Kishtagari, Mojtaba Akhtari, James McCloskey, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas

Blood (2023) 142 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2023-178725

Published: 2023

Journal Articles

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Abdulraheem Yacoub, Roger M. Lyons, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2023-180240

Published: 2023

Journal Articles

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Chen Zhang, Douglas Tremblay, John Magnotti, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Angela G Fleischman, Ruben Mesa, Abdulraheem Yacoub, John Mascarenhas, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 9693–9695.

https://doi.org/10.1182/blood-2022-157873

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

NARROW

Comparative Effectiveness of Chatgpt 4.0 and Gemini Advanced in Diagnosing Challenging Hematologic Cases

Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Systematic Approach to Treatment De-Escalation While Maintaining Remission in CML, a Risk Mitigation and Cost Reduction Study

Pilot Phase II Trial of the Combination of Tagraxofusp with Pacritinib in Patients with Myelofibrosis, Tagpac Study

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Long Term Clinical and Molecular Responses in Patients with Polycythemia Vera and Essential Thrombocytosis Receiving Pegylated Interferon-Alpha Therapy

Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis

Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Durable Clinical Benefits of Idasanutlin Therapy in Hydroxyurea-Refractory Polycythemia Vera

Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera

The Diagnostic Value of Circulating Blasts in Patients with Myeloproliferative Neoplasms in Accelerated or Blast Phase

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only